Increased Relaxant Action of Forskolin and Isoproterenol against Muscarinic Agonist-Induced Contractions in Smooth Muscle from M2 Receptor Knockout Mice
Document Type
Article
Publication Date
2003
Abstract
The ability of forskolin and isoproterenol to inhibit the contractile action of the muscarinic agonist, oxotremorine-M, was investigated in smooth muscle from wild-type and M2 muscarinic receptor knockout mice. Forskolin (5.0 μM) caused a significant reduction in the contractile activity of oxotremorine-M in ileum, trachea, and urinary bladder from both wild-type and M2 muscarinic receptor knockout mice. This reduction in contractile activity was characterized by decreases in potency or maximal response, but not always both. Similar results were obtained with isoproterenol (1.0 μM). The relaxant effects of forskolin in ileum, trachea, and urinary bladder from M2 receptor knockout mice were approximately 3- to 9-fold greater than those observed in the same tissues from wild-type mice. Similar results were obtained with isoproterenol in ileum and urinary bladder, although the differences between wild-type and M2 receptor knockout tissues were less than those observed with forskolin. In contrast, there was no significant difference between the relaxant effect of isoproterenol in trachea from wild-type and M2 receptor knockout mice. In contrast to the results observed with oxotremorine-M as the contractile agent, forskolin and isoproterenol did not exhibit greater relaxant activity against KCl-induced contractions in M2 receptor knockout mice compared with wild-type mice. These results suggest that a component of the contractile response to muscarinic agonists in smooth muscle involves an M2 muscarinic receptor-mediated inhibition of the relaxant effects of agents that increase cAMP levels.
Recommended Citation
Matsui, Minoru, et al. "Increased relaxant action of forskolin and isoproterenol against muscarinic agonist-induced contractions in smooth muscle from M2 receptor knockout mice." Journal of Pharmacology and Experimental Therapeutics 305.1 (2003): 106-113. doi: 10.1124/jpet.102.044701
Copyright
American Society for Pharmacology and Experimental Therapeutics
Comments
This article was originally published in Journal of Pharmacology and Experimental Therapeutics, volume 305, issue 1, in 2003. DOI: 10.1124/jpet.102.044701